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in fat distribution in the ovulatory and anovulatory
phenotypes of polycystic ovary syndrome
Central fat distribution is increased in anovulatory women with polycystic ovary syndrome (PCOS) compared
with ovulatory PCOS and matched controls. Among secreted adipocytokines, this is reflected mainly in lower
levels of adiponectin. (Fertil Steril 2009;91:1332–5. 2009 by American Society for Reproductive Medi-
cine.)Most women with polycystic ovary syndrome (PCOS) have
increased fat quantity and altered fat distribution with in-
creased abdominal adipose tissue (1). In addition, several
studies have shown that women with PCOS exhibit an alter-
ation in the secretion of adipose products that may contrib-
ute to insulin resistance and cardiovascular risk (2–4).
Among these alterations, particularly important is the re-
duction in circulating adiponectin levels, which may play
a significant role in the early endothelial abnormalities of
young women with PCOS (4–9).
Some initial reports have found elevated levels of serum
visfatin (10–12) and retinol-binding protein 4 (RPB4) (13,
14) compared with control women of similar body weight,
although the data have not been entirely consistent. Al-
though the finding of increased RBP4 may be expected be-
cause of the known increased insulin resistance of women
with PCOS (13, 15), the cause for the elevation of visfatin,
if present, remains unclear.
Differences in results may be related to heterogeneity
among the patients studied with PCOS, given the expanded
diagnostic criteria for the diagnosis of PCOS, which in-
cludes ovulatory hyperandrogenic women (14, 15), and an-
ovulatory normoandrogenic women (14). It is known that
some of these phenotypes have milder insulin resistance
and reduced markers of cardiovascular risk (16–18).
Our study assessed fat distribution and the circulating
levels of several well-established (adiponectin and leptin)
and newer (visfatin and RPB4) adipocytokines in women
with PCOS with different phenotypes as well as in matched
controls. Our aim was to determine if fat distribution is al-
tered in women with different phenotypes, and whether
Received November 17, 2007; revised and accepted March 5, 2008;
published online May 2, 2008.
E.C. has nothing to disclose. S.B. has nothing to disclose. P.M. has noth-
ing to disclose. G.R. has nothing to disclose. M.F. has nothing to dis-
close. R.A.L. has nothing to disclose.
Reprint requests: Rogerio A. Lobo, M.D., Department of Obstetrics and
Gynecology, Columbia University Medical Center, 622 West 168
Street, Rm. 16-69, New York, NY 10032 (FAX: 212-305-4326;
E-mail: ral35@columbia.edu).ity and Sterility Vol. 91, No. 4, Supplement, April 2009
right ª2009 American Society for Reproductive Medicinethere are changes in adipocytokine secretion which in turn
may relate to insulin resistance.
Forty-eight women of reproductive age with PCOS, all
referred to the Palermo Endocrine Unit because of androgen
excess and who were seen consecutively, were included in
our study. The diagnosis of PCOS was based on the pres-
ence of clinical or biologic hyperandrogenism associated
with chronic anovulation and/or the finding of polycystic
ovaries on ultrasound scan (15). In all patients, adrenal en-
zymatic deficiency (by measurement of serum 17-hydroxy-
progesterone), Cushing syndrome, or androgen secreting
tumors were excluded.
Biochemical hyperandrogenism was defined as serum
testosterone (T) >60 ng/dL and/or free T R3 pg/mL and/
or serum dehydroepiandrosterone sulfate (DHEAS)
R3000 mg/L. That these values signify hyperandrogenism
has been reported previously in our population using the
same assays (19).
Anovulation was defined as serum progestogen (P) <3
ng/mL. In patients with normal menses, at least two consec-
utivemenstrual cycles were studied, and the finding of a low
serum P (<3 ng/mL) level in both cycles indicated the pres-
ence of anovulation. This study included both anovulatory
(n¼ 34) and ovulatory (n¼ 14) womenwith PCOS (16, 17).
The presence of polycystic ovaries was determined by
transvaginal sonography. The finding of increased ovarian
size (20) and/or of at least 12 follicular cysts measuring 2
to 9 mmwere considered indicative of the presence of poly-
cystic ovaries (21).
The study design included a medical examination, bio-
chemical analyses, and dual energy x-ray absorptiometry
(DEXA) determinations of fat quantity and distribution. Ex-
cluded from the study were women with renal or hepatic
diseases, and type II diabetes; no women received any med-
ications for at least 3 months before the study. Fat quantity
was determined by total body DEXA using a similar Instru-
ment (QDR-Discovery; Hologic, Bedford, MA). Total fat
quantity and quantity of fat in the trunk area were measured.
Quantity of fat also was determined as the central0015-0282/09/$36.00
, Published by Elsevier Inc. doi:10.1016/j.fertnstert.2008.03.007
Fabdominal area (R1 area), an area of 50 cm2 around the cen-
tral point of the midline between the lateral iliac crests and
the lowest rib margin at the end of a normal expiration (the
same midline used for waist circumference) (1). The central
point of R1 area did not always correspond to the umbilicus.
To assess fat distribution, percentage of total fat in the trunk
and R1 area were calculated.
As controls, we selected a group of 20 healthy women
matched for age and body mass index (BMI) using the
same exclusion criteria described above. Controls were
women with regular menses, no clinical or biologic hyper-
androgenism, and normal serum progesterone levels (>7
ng/mL day 22 of the cycle). No patients or controls had
a BMI higher than 40.
In all women with PCOS and in normal controls, during
the follicular phase (days 5 to 8), a fasting blood sample was
obtained between 8:00 and 9:00 AM for measurements of lu-
teinizing hormone (LH), estradiol, testosterone, leptin, adi-
ponectin, visfatin, RBP4, insulin, glucose, total cholesterol,
high-density lipoprotein (HDL) cholesterol, low-density li-
poprotein (LDL) cholesterol, and triglycerides as well as
c-reactive protein (CRP) (22–25). Insulin resistance was
calculated by the Quantitative Insulin-Sensitivity Check In-
dex (QUICKI) (26). In all hormonal assays, the intra-assay
coefficient of variation was <6%, and the interassay coeffi-
cient of variation was <15%.
Adiponectin and leptin were measured by enzyme-linked
immunosorbent assay (ELISA) systems purchased from Di-
agnostic Systems Laboratories, Inc. (Webster, TX). Visfatin
was measured by a visfatin C-terminal (human) enzyme im-
munoassay (Phoenix Pharmaceuticals, Belmont, CA) with
a sensitivity of 3 ng/mL. Human recombinant full-length
visfatin had a 100% cross-reactivity. Retinol-binding pro-
tein 4 was measured by ELISA (ALPCO Diagnostics,
Windham, NH) with a sensitivity of 0.9 ng/mL.
The protocol and procedures were approved by the local
institutional review board, and all patients consented to par-
ticipate in this study.
Statistical analyses were performed using Statview 4.5
(Abacus Concepts Inc., Berkeley, CA) and SPSS 9.0 for
PC (SPSS Inc., Chicago, IL). Univariate analyses were per-
formed using Student’s unpaired t-test for the numeric vari-
ables, and the differences in the prevalence of the nominal
variables were analyzed by chi-square test. Analysis of
covariance (ANCOVA) was used to assess the differences
in fat quantity and distribution and in the biochemical pa-
rameters between subgroups of patients and controls. Cor-
relation analyses were performed using the Spearman
rank correlation method. All data are expressed as mean
 standard deviation (SD).
Patients with PCOS and matched controls were of similar
age (27.3 6.4 years vs. 27.7 4.5 years) and BMI (27.1
5.6 vs. 26.8  3.9), and had a similar total fat quantityertility and Sterility(26446  9158 g vs. 26667  9136 g). Trunk fat quantity
(10938  5179 g vs. 10890  4058 g), percentage of trunk
fat (39.6 5.6% vs. 38.6 4.4%), and R1 fat quantity (728
 350 g vs. 654  245 g) were similar in the two groups
whereas waist circumference (91.1  13.9 cm vs. 85.5 
5.4 cm, P<.05) and percentage of R1 fat (2.66  0.54%
vs. 2.36  0.24%, P<.01) were statistically significantly
higher in women with PCOS.
The women with PCOS had increased levels of LH, T, in-
sulin, lower QUICKI, lower HDL cholesterol, and higher
triglycerides (all P<.01) compared with matched controls.
Leptin was similar in both groups, but circulating adipo-
nectin was lower (P<.01), and visfatin (P<.01), RBP4
(P<.05), and CRP (P<.01) were higher in women with
PCOS compared with matched controls. Serum leptin cor-
related positively and adiponectin negatively (P<.01)
with all fat parameters (P<.01). Serum visfatin and RBP4
did not correlate with any fat parameter.
Retinol-binding protein 4 correlated with levels of serum
LH (r ¼ 0.35, P<.05) and estradiol (r ¼ 0.40, P<.05), and
these correlations were independent of BMI or fat quantity.
No other correlations between adipose products and gonad-
otropin or steroid values were found.
In classic (anovulatory) PCOS, waist circumference was
statistically significantly larger (93.2  14.9 vs. 86  8.5
cm, P<.05) and trunk fat, R1 fat, percentage of trunk fat,
and percentage of R1 fat were statistically significantly
greater (P<.05) than in ovulatory women with PCOS. Com-
pared with controls, ovulatory PCOS patients had similar
fat parameters, including waist circumference, percentage
of trunk fat, and percentage of R1 fat, whereas patients
with classic PCOS, despite being of similar BMI and having
similar total fat, had larger waist circumferences (P<.05)
and higher trunk R1 fat and percentage of trunk and percent-
age of R1 fat. Patients with classic PCOS had higher insulin
(P<.01), lower QUICKI (P<.01) values, and higher LH
levels than the ovulatory group, and their levels were higher
compared with matched controls.
C-reactive protein was higher in classic PCOS versus
ovulatory PCOS. Leptin, visfatin, and RBP4 were similar
in the two subgroups of women with PCOS, but adiponectin
was statistically significantly lower in the anovulatory
group (Fig. 1). Comparing the serum levels of the adipocy-
tokines in both phenotypes with those of the matched con-
trols, it was observed that classic (anovulatory) PCOS
patients had increased serum visfatin and RBP4 and lower
levels of adiponectin while ovulatory PCOS patients had
higher serum visfatin and RBP4 but similar levels of adipo-
nectin compared with matched controls (see Fig. 1).
Our study assessed for the first timewhether there are dif-
ferences in body fat distribution as well as in certain adipo-
cytokines between women with classic and ovulatory
phenotypes, and whether these parameters may relate to1333
differences in insulin sensitivity. We were limited in our
ability to assess insulin sensitivity other than by measures
of QUICKI, which in our hands correlates well with other
methods (27).
Our data suggest that fat distribution is normal in women
with ovulatory PCOS and is similar to that found in controls
when matched for total fat and BMI. Anovulatory women
with classic PCOS have greater abdominal adiposity in spite
of similar BMI. Our patients with ovulatory PCOS who had
normal fat distribution had insulin levels and insulin sensi-
tivity that were similar to those of matched controls. Previ-
ous data have found women with ovulatory PCOS to have
insulin levels that were slightly but significantly higher
compared with controls, but lower than in patients with
classic PCOS (17). Other studies, however, have reported
normal insulin levels in this subgroup of patients with
PCOS (18, 28). It is clear that there is heterogeneity in the
degree of insulin sensitivity in women with PCOS who
have ovulatory function, and this may relate to the specifics
of the group studied, including variations such as age, BMI,
ethnicity, and the method for determining insulin sensitivity
(as already noted). However, in spite of normal fat distribu-
tion and insulin parameters, women with ovulatory PCOS
were found to have increased levels of visfatin and RBP4,
which were similar to those found in classic PCOS.
The findings of elevated visfatin in PCOS, in spite of
a lack of correlation with fat mass or insulin, is intriguing
and needs to be studied further. This relationship also ex-
isted for RBP4, which showed an interesting and novel
small but statistically significant correlation between
FIGURE 1
Comparison of serum levels of the adipocytokines
in ovulatory and anovulatory polycystic ovary
syndrome with controls. *P< .05 versus controls.
**P< .01 versus controls. **^P< .005 versus
ovulatory PCOS.
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that more work in this area will be forthcoming in that these
newer assays are currently available commercially.
However, adiponectin was statistically significantly
decreased in women with the classic syndrome but not in
women with ovulatory PCOS (see Fig. 1). Serum adiponec-
tin correlated with fat distribution, confirming that abdomi-
nal fat is perhaps the principal factor influencing adiponectin
secretion (4).
We have shown that patients with ovulatory PCOS have
a similar fat distribution to matched controls but altered
levels of visfatin and RBP4. The relationship of the latter
more novel observations to insulin dynamics in PCOS re-
mains to be determined. Our data further underscore the sig-
nificant metabolic and hormonal differences in these two
phenotypes of PCOS, warranting caution in the interpreta-
tion of studies that do not differentiate between various
types of patients.
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